IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Examiner: SHIAO, Rei Tsang

NAZARE, et al.

1626

Application No.: 10/849,089

Art Unit:

Filed: 05/19/2004

Title: AZAINDOLE-DERIVATIVES AS FACTOR

XA INHIBITORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it is submitted: (1) Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); (2) Within three months of the date of entry of the national stage as set forth in §1.491 in an international application; (3) Before the mailing of a first Office Action on the merits, or (4) Before the mailing of a first Office action after the filing of a request for continued examination under §1.114. In the event, however, that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

| (b) | This | Information Disclosure Statement is filed after the period set forth in 37 C.F.R. |
|-----|------|---|
| | 1.97 | (b), but is believed to be filed before the mailing date of a final action under §1.113 |
| | or a | notice of allowance under §1.311, whichever occurs first. |
| | (1) | The undersigned attorney certifies that each item of information contained in this |
| | | Information Disclosure Statement was cited in a communication from a foreign |
| | | patent office in a counterpart foreign application not more than three months prior |
| | | to the filing of this statement; |
| | (2) | The undersigned attorney certifies that no item of information contained in this |
| | | Information Disclosure Statement was cited in a communication from a foreign |
| | | patent office in a counterpart foreign application or, to the knowledge of the |
| | | undersigned attorney after making reasonable inquiry, was known to any |
| | | individual designated in $\S1.56(c)$ more than three months prior to the filing of this |
| | | statement; or |
| | (3) | This Information Disclosure Statement is accompanied by a transmittal letter in |
| | | which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is |
| | | authorized. |
| | | |

Respectfully submitted,

Jiang Lin, Reg. No. 51,065 Attorney for Applicant

June 8, 2007 Dated

sanofi-aventis U.S. LLC Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3582 Telefax (908) 231-2626

Aventis Docket No. DEAV2003/0033 US NP

Approved for use through 1091/93, CMB 5651-031

Patent and Frademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Payerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it commisses a valid CMB control number.

| Substitt | tie for form 1449A/F | то | | Complete if Known | | | |
|----------|----------------------|----------|--------------|------------------------|-------------------------|--|--|
| | 0011110 | | 201 001175 | Application Number | 10/849,089 | | |
| | | | SCLOSURE | Filing Date | 05-19-2004 | | |
| STA | TEMENT | BYA | PPLICANT | First Named Inventor | NAZARÉ, et al. | | |
| | | | . / | Group Art Unit | 1626 | | |
| | (use as many s | heels as | s necessary) | Examiner Name | SHIAO, Rei Tsang | | |
| Sheet | 1 | of | 1 | Attorney Docket Number | DEAV2003/0033 - US - NP | | |

| | U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|-------------|--|--|--|--|--|
| Examiner Initials* | Cite No.1 | U.S. Patent | Document Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Ralevent Passages or Relevant Frantse Appear | |
| | | US2004-0204 | 406 | NAZARĖ, et al. | 10-14-2004 | | |
| | | 11/469,513 | | URMANN, et al. | 09-01-2006 | | |
| | | US2004-0171 | 604 | NAZARÉ, et al. | 09-02-2004 | | |
| | | US2004-0235 | 824 | NAZARĖ, et al. | 11-25-2004 | *************************************** | |
| | | US2005-0009 | 829 | NAZARÉ, et al. | 01-13-2005 | | |
| | | US2005-0009 | 827 | NAZARÉ, et al. | 01-13-2005 | | |
| | | US2005-0033 | 049 | NAZARÉ, et al. | 02-10-2005 | | |
| | | US2005-0043 | 302 | NAZARÉ, et al. | 02-24-2005 | | |
| | | 6,906,084 | | NAZARÉ, et al. | 06-14-2005 | | |
| | | 6,953,857 | | NAZARÉ, et al. | 10-11-2005 | | |
| | | 7,067,665 | | NAZARÉ, et al | 06-27-2006 | | |
| | | 11/467,277 | | BAUER, et al | 08-25-2006 | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | *************************************** | |

| | FOREIGN PATENT DOCUMENTS | | | | | | | |
|-----------------------|--------------------------|---------------------|---|--|--|--|--|----------|
| Examiner Initials* | Cite No.1 | Office ³ | oreign Patent Do Number ⁴ | Cument Kind Code ^s (if known) | Name of Petentee or Applicant of Cited Document | Date of Publication of Cited Decument MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Pigures Appens | γo |
| | | \vdash | | -++ | | | | - |
| | | | | | | | | ļ |
| | | | | | | | | Ħ |
| | | | | | | | | \vdash |
| | | | | | | | | ╁ |
| | | | | | | | | t |

| - | Examiner | Date | |
|---|-----------|-------------|---------|
| - | Signature | Considered | |
| | | | <u></u> |

*EXAM/INER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

** Unsize catation designation number * See attached Kinds of U.S. Planto Documents. ** Eath of Use the last swort the document, by this love laster could KIVFO Standard ST.3.* * For Improved patter document, be included not be year of the right of the Emperor must provide this swrat number of the patient document. ** KIND of document by the appropriate symbols as indicated on the document under VMIPO Standard ST.1 5 if possible. ** Application is to place to the document without without standard ST.1 5 if possible. ** Application is to place to the document.

